CF PharmTech buys back HKD 0.35 million of shares, treasury stock rises to 613,000

Bulletin Express04-23

CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025.

Key transaction details • Shares repurchased: 16,500 ordinary H-shares, acquired on the Hong Kong Stock Exchange. • Price range: HKD 20.90–21.34 per share; volume-weighted average price: HKD 21.10. • Cash outlay: HKD 348,200 (approximately 0.35 million).

Impact on share capital • Issued shares (excluding treasury) fell to 301.61 million from 301.63 million. • Treasury shares increased to 613,000, bringing total issued shares (including treasury) to 302.22 million, unchanged from the prior day.

Repurchase mandate utilisation • Authorised capacity: 30.22 million shares. • Cumulative repurchases since the mandate: 613,000 shares, equivalent to 0.20 % of the issued share base on the mandate date.

Regulatory window Under Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026, 30 days after the latest buyback.

The board confirmed that all repurchase procedures complied with Hong Kong listing rules and relevant regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158174705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158174705","market":"us","top_or_hot":-1,"title":"CF PharmTech buys back HKD 0.35 million of shares, treasury stock rises to 613,000","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025.</p>\n<p>Key transaction details  \n• Shares repurchased: 16,500 ordinary H-shares, acquired on the Hong Kong Stock Exchange.  \n• Price range: HKD 20.90–21.34 per share; volume-weighted average price: HKD 21.10.  \n• Cash outlay: HKD 348,200 (approximately 0.35 million).</p>\n<p>Impact on share capital  \n• Issued shares (excluding treasury) fell to 301.61 million from 301.63 million.  \n• Treasury shares increased to 613,000, bringing total issued shares (including treasury) to 302.22 million, unchanged from the prior day.</p>\n<p>Repurchase mandate utilisation  \n• Authorised capacity: 30.22 million shares.  \n• Cumulative repurchases since the mandate: 613,000 shares, equivalent to 0.20 % of the issued share base on the mandate date.</p>\n<p>Regulatory window  \nUnder Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026, 30 days after the latest buyback.</p>\n<p>The board confirmed that all repurchase procedures complied with Hong Kong listing rules and relevant regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech buys back HKD 0.35 million of shares, treasury stock rises to 613,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech buys back HKD 0.35 million of shares, treasury stock rises to 613,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-23 21:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025.</p>\n<p>Key transaction details  \n• Shares repurchased: 16,500 ordinary H-shares, acquired on the Hong Kong Stock Exchange.  \n• Price range: HKD 20.90–21.34 per share; volume-weighted average price: HKD 21.10.  \n• Cash outlay: HKD 348,200 (approximately 0.35 million).</p>\n<p>Impact on share capital  \n• Issued shares (excluding treasury) fell to 301.61 million from 301.63 million.  \n• Treasury shares increased to 613,000, bringing total issued shares (including treasury) to 302.22 million, unchanged from the prior day.</p>\n<p>Repurchase mandate utilisation  \n• Authorised capacity: 30.22 million shares.  \n• Cumulative repurchases since the mandate: 613,000 shares, equivalent to 0.20 % of the issued share base on the mandate date.</p>\n<p>Regulatory window  \nUnder Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026, 30 days after the latest buyback.</p>\n<p>The board confirmed that all repurchase procedures complied with Hong Kong listing rules and relevant regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1158174705","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158174705","pubTimestamp":1776950636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025. Key transaction details   • Shares repurchased: 16,500 ordinary H-shares,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购35万港元库存股升至61.3万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025.\nKey transaction details  \n• Shares repurchased: 16,500 ordinary H-shares, acquired on the Hong Kong Stock Exchange.  \n• Price range: HKD 20.90–21.34 per share; volume-weighted average price: HKD 21.10.  \n• Cash outlay: HKD 348,200 (approximately 0.35 million).\nImpact on share capital  \n• Issued shares (excluding treasury) fell to 301.61 million from 301.63 million.  \n• Treasury shares increased to 613,000, bringing total issued shares (including treasury) to 302.22 million, unchanged from the prior day.\nRepurchase mandate utilisation  \n• Authorised capacity: 30.22 million shares.  \n• Cumulative repurchases since the mandate: 613,000 shares, equivalent to 0.20 % of the issued share base on the mandate date.\nRegulatory window  \nUnder Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026, 30 days after the latest buyback.\nThe board confirmed that all repurchase procedures complied with Hong Kong listing rules and relevant regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158174705","isCrawlerRequest":true}